Overview
Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain
Status:
Terminated
Terminated
Trial end date:
2008-02-01
2008-02-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in relieving Irritable Bowel Syndrome pain. The study is being conducted in 2 parts. Part A enrolled 213 pts dosed with either 3, 20, 60 mg AGN 203818 or placebo over 4 week treatment duration. Part B will enroll 320 pts and dose with either 60, 100, 160 mg BID AGN 203818 or placebo over 12 week treatment duration.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Allergan
Criteria
Inclusion Criteria:- Diagnosis of Irritable Bowel Syndrome
- Moderate or severe IBS pain
Exclusion Criteria:
- Any other uncontrolled disease
- Pregnant or nursing females